Through collaboration and investment, we transform promising medical research breakthroughs into medical therapies that improve patients lives. We have supported more than 50 start-up companies to date, the majority of which were founded by us.
From early-stage seed investment through to expansion capital, we support life science companies from proof-of-concept through to commercialisation. In ANZ, we source and create our deals through Brandon BioCatalyst (formerly the Medical Research Commercialisation Fund), a unique collaboration of Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Our team are professionals with technical, business and operational experience. We partner with entrepreneurs and have a proven track record of establishing successful, long-term relationships with our management teams. We know what it takes to maximise the chance of success for a life science company and this expertise is directed toward supporting our portfolio companies to a successful outcome.
We’re at the forefront of contributing to the growth of a high-value, sustainable biotech industry which delivers jobs, wealth and improves patient outcomes in Australia, New Zealand, and globally.
